{
    "Trade/Device Name(s)": [
        "VITROS B\u2022R\u2022A\u2022H\u2022M\u2022S PCT Reagent Pack",
        "VITROS B\u2022R\u2022A\u2022H\u2022M\u2022S PCT Calibrators",
        "VITROS Immunodiagnostic Products B\u2022R\u2022A\u2022H\u2022M\u2022S PCT Reagent Pack and Calibrators"
    ],
    "Submitter Information": "Ortho-Clinical Diagnostics, Inc.",
    "510(k) Number": "K200236",
    "Predicate Device Reference 510(k) Number(s)": [
        "K171338"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PRI",
        "NTM",
        "PMT"
    ],
    "Summary Letter Date": "January 29, 2020",
    "Summary Letter Received Date": "January 30, 2020",
    "Submission Date": "January 29, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.3215"
    ],
    "Regulation Name(s)": [
        "Device to detect and measure non-microbial analyte(s) in human clinical specimens to aid in assessment of patients with suspected sepsis"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Procalcitonin (PCT)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (lithium heparin)",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 3600 Immunodiagnostic System"
    ],
    "Method(s)/Technology(ies)": [
        "Two-step dual monoclonal immunometric assay",
        "Chemiluminescent detection"
    ],
    "Methodologies": [
        "Immunometric assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent Pack"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS B\u2022R\u2022A\u2022H\u2022M\u2022S PCT immunometric assay measuring procalcitonin on VITROS 3600 for risk assessment in sepsis and infection management.",
    "Indications for Use Summary": "For quantitative measurement of procalcitonin in serum and plasma on VITROS 3600 system to aid in sepsis risk assessment, 28-day mortality prediction, and antibiotic therapy decision-making in critically ill patients.",
    "fda_folder": "Microbiology"
}